This study is currently not recruiting participants.

A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12 Anti-IGF-IR Monoclonal Antibody IND #100947 NSC #7424601]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma

Study of Investigational Medication with Chemotherapy for High-Risk Rhabdomyosarcoma (a type of cancer in soft tissue)

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

In this study researchers want to find out what effects using IMC A12 in combination with high intensity chemotherapy will have on subjects with high risk rhabdomyosarcoma.

Detailed description of study

In this study researchers want to find out what effects using IMC A12 in combination with high intensity chemotherapy will have on subjects with high risk rhabdomyosarcoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rhabdomyosarcoma
  • Age: 100 years or below
  • Gender: All

This study investigates the effects of using an investigational medication in combination with high-intensity chemotherapy on patients with high-risk rhabdomyosarcoma. Rhabdomyosarcoma is a type of cancer that forms in soft tissue, such as muscles, and is considered high-risk when it is more likely to spread or come back after treatment.

Participants in the study will receive either the investigational medication along with chemotherapy or a placebo with chemotherapy. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.

  • Who can participate: Individuals diagnosed with high-risk rhabdomyosarcoma may be eligible to participate. Specific eligibility criteria, including age, are not provided.
  • Study details: Participants will receive either the investigational medication or a placebo along with chemotherapy.
Updated on 19 Feb 2024. Study ID: 1106005969

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team